Knee

SAN DIEGO — A single injection of TLC599, a liposomal formulation of dexamethasone sodium phosphate, bested placebo for osteoarthritis knee pain over 24 weeks, while a second injection extended benefits to week 52, according to data.

Intra-articular injections of autologous adipose-derived stem cells or adipose-derived stromal vascular fraction significantly improve pain and function in knee osteoarthritis, according to data published in Arthritis Research & Therapy.

EP-104AR, an injectable form of fluticasone propionate designed slowly distribute through the knee joint and provide pain relief for up to 6 months, improved pain vs. a placebo over 12 weeks, according to the manufacturer.

Knee acoustic emissions may be an “inexpensive and easy-to-use” biomarker to help differentiate between patients with and without juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

Patients with hip or knee osteoarthritis who exercise fare better than patients who do not, with those demonstrating worse severity and function at baseline benefitting most acutely, according to data published in The Lancet Rheumatology.

A 28-year-old male soccer player presented with acute onset of left knee pain and swelling following an awkward twisting motion during a game.

A 0.5 mg daily dose of colchicine was linked to a 31% lower incidence of total knee and total hip replacement in patients with chronic coronary artery disease compared with placebo, according to an exploratory analysis of the LoDoCo2 trial.

The American College of Rheumatology and the American Association of Hip and Knee Surgeons recently issued new recommendations on the optimal timing of elective hip or knee replacement.

According to published results, patients with limited English proficiency are less likely to undergo revision surgery within 1 to 2 years of total joint arthroplasty compared with patients who are proficient in English.

Although the Smith & Nephew Genesis II and Journey II bicruciate stabilized knee implants had no differences in 6-month patient-reported outcomes, results showed the Genesis II yielded significant advantages for knee range of movement.